Claire Mazumdar
Amministratore Delegato presso Bicara Therapeutics, Inc.
Posizioni attive di Claire Mazumdar
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Bicara Therapeutics, Inc.
 Bicara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bicara Therapeutics, Inc. is a company that develops first-in-class bifunctional antibodies for the treatment of solid tumors. The company is based in Cambridge, MA. The company's lead product candidate, bca101, is a first-in-class egfr/tgf-?-trap bifunctional antibody in clinical development for multiple tumor types. The company's bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Bicara has a deep pipeline of promising bifunctional antibodies and other biologics for treating solid tumors. The CEO of the company is Claire Mazumdar. | Direttore/Membro del Consiglio | - | - |
| Amministratore Delegato | - | - | |
| Presidente | - | - |
Storia della carriera di Claire Mazumdar
Statistiche
Distribuzione geografica
| Stati Uniti | 2 |
Posizioni
| Director/Board Member | 1 |
| Chief Executive Officer | 1 |
| President | 1 |
Settori
| Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 1 |
|---|---|
Bicara Therapeutics, Inc.
Bicara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bicara Therapeutics, Inc. is a company that develops first-in-class bifunctional antibodies for the treatment of solid tumors. The company is based in Cambridge, MA. The company's lead product candidate, bca101, is a first-in-class egfr/tgf-?-trap bifunctional antibody in clinical development for multiple tumor types. The company's bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Bicara has a deep pipeline of promising bifunctional antibodies and other biologics for treating solid tumors. The CEO of the company is Claire Mazumdar. | Health Technology |
- Borsa valori
- Insiders
- Claire Mazumdar
- Esperienza
